Business Context and Reporting Period
This Form 8-K Current Report for Senseonics Holdings, Inc. covers events occurring on September 30, 2020, with the report filed on October 6, 2020. The filing primarily addresses Item 5.02 regarding the appointment of two new directors to the Board of Directors, effective October 1, 2020.
Key Financial Metrics
The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, or liquidity ratios for the reporting period. However, it details specific capital transactions and compensation arrangements:
- Debt Financing: Issuance of $35.0 million in aggregate principal amount of Senior Secured Convertible Notes due in October 2024 to PHC Holdings Corporation.
- Equity Financing Fee: Issuance of 2,941,176 shares of common stock to PHC as a financing fee, valued at $1.4 million based on the August 9, 2020 closing price.
- Preferred Stock Sale: Sale of 3,000 shares of Series A Preferred Stock to Masters Special Situations, LLC at $1,000.00 per share ($3.0 million total).
- Consulting Fees: Agreement to pay Masters Special Situations, LLC a consulting fee of $150,000 per year.
- Director Compensation: Anthony Raab granted 273,077 restricted stock units (vesting October 1, 2021) and an annual retainer of $37,500. Robert Schumm will receive no compensation as a director.
Material Changes
The primary material change is the expansion of the Board of Directors and the execution of strategic agreements with major investors:
- Board Appointments: Robert Schumm (Class I director, term expires 2023) and Anthony Raab (Class II director, term expires 2021) were appointed.
- Commercial Partnership: A Collaboration and Commercialization Agreement was entered with Ascensia Diabetes Care Holding AG (an affiliate of PHC) to distribute Eversense products globally for an initial five-year term. Ascensia will receive a portion of net revenue at tiered percentages ranging from the mid-teens to the mid-forties.
- Investor Rights: Appointments were made pursuant to Investor Rights Agreements with PHC Holdings Corporation and Masters Special Situations, LLC.
Guidance, Outlook, and Risks
The filing does not contain forward-looking financial guidance or specific risk factors beyond the standard contingencies associated with the new agreements:
- Contingent Equity: The Company has an option to sell up to $15.0 million of convertible preferred stock to PHC by December 31, 2022, contingent upon stockholder approval and FDA approval for the 180-day Eversense product.
- Future Equity Issuance: Masters Special Situations, LLC has an option to purchase up to an additional 27,000 shares of Series A Preferred Stock, subject to stockholder approval to increase authorized common stock.
- Operational Roles: Under the Ascensia agreement, Senseonics remains responsible for product development, manufacturing, and regulatory submissions, while Ascensia handles sales, marketing, and market access.
Key Facts for Investor Verification
- Verify the terms of the $35.0 million Senior Secured Convertible Notes issued to PHC, including interest rates and conversion terms.
- Confirm the status of stockholder approvals required for the potential issuance of $15.0 million in convertible preferred stock to PHC and the additional Series A Preferred Stock to Masters.
- Monitor the regulatory approval timeline for the Eversense 180-day product, which is a condition precedent for certain equity issuances.
- Review the specific tiered revenue share percentages Ascensia will receive from global net revenues.
- Assess the impact of the new board members' backgrounds (Ascensia leadership and Masters Capital Management) on future strategic direction.